8-K/A: PetVivo Holdings Secures $5 Million Equity Financing Through Series B Convertible Preferred Stock Offering

PetVivo Holdings, Inc. announces a $5 million equity financing agreement through the issuance of Series B Convertible Preferred Stock, with an initial $600,000 received and an option for the investor to purchase the remaining $4.4 million within 60 days.

Summary

• PetVivo Holdings, Inc. has entered into a Subscription Agreement to receive $5,000,000 in equity financing.
• This financing is in exchange for 5,000,000 shares of Series B Convertible Preferred Stock.
• The company received an initial $600,000 on March 26, 2025.
• The investor has an option to invest the remaining $4,400,000 within the next 60 days under the same terms.
• The offering is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
• The Series B Preferred Stock will have restricted securities status under Rule 144.
• Each holder of Series B Convertible Preferred Stock shall have that number of votes on all matters submitted to the shareholders that is equal to the number of shares of Common Stock into which such holders shares of Series B Convertible Preferred Stock are then convertible.
• The Series B Preferred Stock is entitled to receive a specific dividend in an annual amount equal to Ten Percent (10%) of the total amount paid to secure the Series B Convertible Preferred Stock.
• The dividend shall be paid to the holder by the Company in quarterly payments of Company Common Stock.
• Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, no distributions of available funds and assets will be made to the holders of Common Stock until the holders of Series B Preferred Stock and Series A Preferred Stock receive a per share amount equal to the original issue price.
• The Series B Preferred Stock is convertible, at the option of the holder thereof upon written notice to the Company, into an equal number of shares of Common Stock to the total number of shares of Series B Preferred Stock converted (e.g. one share of Series B Preferred Stock for one share of Common Stock).
• Following the second year anniversary of the issuance of the Series B Convertible Preferred Stock, the Company shall have the right, at its discretion, to call for the purchase of all or a portion of the shares of Series B Convertible Preferred Stock (Call Option) by providing the Holder written notice of the intent to exercise the Call Option on the thirtieth (30th) day from the receipt of notice by the Holder.
• The call price for each share of Series B Convertible Preferred Stock the Company desires to purchase pursuant to the Call Option shall be at a price of One Dollar and Fifteen Cents ($1.15) per share.
• PetVivo intends to use the net proceeds from this offering primarily for commercialization of its lead products Spryng with OsteoCushion Technology and PrecisePRP, to finance clinical trials and to fund working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The announcement of $5 million in equity financing is generally positive, indicating investor confidence and providing capital for growth. However, the terms of the preferred stock and potential dilution temper the overall sentiment.

Positives

• The $5 million equity financing strengthens PetVivo's financial position.
• The initial $600,000 provides immediate capital for operations.
• The investor's option to purchase an additional $4.4 million offers potential for further funding.
• The 10% dividend on the Series B Preferred Stock could attract investors.
• The company call option after two years provides flexibility for capital management.
• The funds will be used to commercialize key products and fund clinical trials.

Negatives

• The Series B Preferred Stock comes with dividend obligations, potentially impacting cash flow.
• The investor's conversion option could dilute existing shareholders' equity.
• The company is relying on the judgment of management regarding the application of the net proceeds of this offering.
• The offering price of the Shares has been determined arbitrarily by the management of PetVivo, and bears no particular relationship to our net worth, revenues or any other standard criteria of value.

Risks

• The success of commercialization efforts, cash generated from future operations, and actual expenses to operate our business may vary significantly from our current intentions.
• The company's management will have broad discretion in the application of the net proceeds.
• The investment is speculative and involves a high degree of risk, and that this investment is only suitable for persons who can afford the entire loss of this investment, and that the economic benefits of this investment are uncertain.
• The investment is not liquid in case of an emergency or for any other reason.
• The Shares have not been registered under the Securities Act of 1933 or any relevant state securities laws, in reliance on exemptions from registration which depend in part upon Subscribers investment intent herein.

Future Outlook

The company anticipates receiving the remaining $4.4 million of the Offering proceeds within the next sixty days of execution of the Subscription Agreement. PetVivo intends to use the net proceeds from this offering primarily for commercialization of its lead products Spryng with OsteoCushion Technology and PrecisePRP, to finance clinical trials and to fund working capital and general corporate purposes.

Industry Context

The financing allows PetVivo to further develop and commercialize its animal health products, potentially increasing its market share in the competitive veterinary medicine industry. This type of funding is common for companies in the animal health sector looking to expand their product lines and market reach.

Comparison to Industry Standards

• Similar companies in the animal health industry, such as Zoetis and Elanco, often utilize equity financing to fund research and development, clinical trials, and commercialization efforts.
• The 10% dividend rate on the Series B Preferred Stock is relatively high compared to standard dividend yields in the broader market, potentially reflecting the higher risk associated with investing in a smaller, growth-oriented company.
• The company call option at $1.15 per share provides PetVivo with a mechanism to manage its capital structure if the company's stock price appreciates significantly.

Stakeholder Impact

• Shareholders may experience dilution if the investor converts the preferred stock to common stock.
• Employees may benefit from increased investment in product development and commercialization.
• Customers may see improved product offerings and availability.
• The company's financial stability could improve, benefiting suppliers and creditors.

Next Steps

• The investor is expected to decide whether to invest the remaining $4.4 million within 60 days.
• PetVivo will utilize the proceeds for commercialization, clinical trials, and working capital.
• The company will issue quarterly dividend payments in Company Common Stock to the holder of the Series B Convertible Preferred Stock.

Key Dates

Keywords

Series B Convertible Preferred Stock, Equity Financing, Subscription Agreement, PetVivo Holdings, Capital Raise, Preferred Stock, Convertible Stock, Financing